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Abstract 
 
Introduction. Although poly(ADP-ribose) polymerase-1 (PARP1) inhibition is a 
recent promising therapy in breast cancer, PARP1 expression in this disease is not 
known.  
Methods. Using DNA microarray and array-based comparative genomic 
hybridization (arrayCGH), we examined PARP1 mRNA expression and copy number 
alterations in 326 invasive breast cancer samples and normal breast samples. A 
meta-analysis was performed on a large public retrospective gene expression 
dataset (n= 2,485) to analyze correlation between PARP1 mRNA expression and 
molecular subtypes and clinico-pathological parameters. 
Results. PARP1 was overexpressed in 58% of cancers, and its expression 
was heterogeneous between tumors. ArrayCGH data revealed an association 
between mRNA overexpression and gain/amplification at the PARP1 locus (p<1.0E-
8). Meta-analysis showed that PARP1 expression was higher in basal breast cancers 
(p<1.0E-72), but overexpression was also found in other subtypes. PARP1 
expression correlated with high grade, medullary histological type, tumor size and 
worse metastasis-free survival (MFS; HR=1.12 [1.04-1.22], p=0.004) and overall 
survival (HR=1.16 [1.04-1.29], p=0.006). In multivariate analysis, PARP1 expression 
had an independent prognostic value for MFS, which was restricted to patients 
untreated with any adjuvant chemotherapy.   
Conclusion. These data demonstrate overexpression of PARP1 in a large 
number of breast cancers and support the development of PARP inhibitors in basal 
subtype but also potentially in other breast cancer subtypes. 
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Introduction 
 
Poly(ADP-ribose) polymerase-1 (PARP1), the most abundant member of the 
PARP superfamily, is a nuclear chromatin-associated protein involved in a wide 
range of biological processes including cell proliferation, apoptosis, malignant 
transformation, transcriptional regulation and DNA repair. PARP1 is essential to the 
base excision repair of DNA single-strand breaks (SSBs) [1]. In response to DNA 
damage, PARP1 senses and binds to DNA nicks and breaks, resulting in activation of 
catalytic activity, causing poly(ADP)ribosylation of PARP1 itself, as well as other 
acceptor proteins, such as histones and topoisomerases. This modification potentially 
stimulates the recruitment and activity of other components of DNA repair pathways 
[1]. In its absence, DNA SSBs accumulate and degenerate to DNA double-strand 
breaks (DSBs), which are not appropriately repaired if the BRCA pathway is deficient 
or dysfunctional. This is thought to explain the exquisite sensitivity to PARP inhibitors 
of tumors with BRCA inactivation, a concept called “synthetic lethality” [2, 3]. Recent 
clinical evidence confirmed that PARP inhibition is a promising therapeutic strategy 
either as single-agent in BRCA1 or BRCA2-mutated breast cancers [4], or in 
combination with cytotoxic chemotherapy in triple-negative (TN) breast cancers, a 
subgroup that shares many features with BRCA1-mutated tumors [5]. Several PARP 
inhibitors are currently in clinical development. However, until now, PARP1 mRNA 
expression has not been described in breast cancer. A few and relatively small (less 
than 95 samples) studies have been reported in melanoma [6, 7], ovarian cancer [8] 
and colon cancer [9], and showed frequent PARP1 overexpression, associated with 
poor-prognosis histo-clinical features.  
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Here, we explored our gene expression database of 326 breast cancer 
samples profiled using oligonucleotide microarrays. Data were then combined with 12 
publicly available expression datasets, resulting in a total of 2,485 invasive breast 
cancers informative for meta-analysis. Our primary objective was to describe the 
molecular epidemiology of this novel therapeutic target in a large population of early 
breast cancer patients. Secondary objectives included correlation between PARP1 
expression and other clinical, pathological and molecular features, including survival. 
 
 
Patients and Methods 
 
Gene expression data of breast cancer 
To determine PARP1 mRNA expression in breast cancer, we analyzed gene 
expression data of 326 breast tumor samples that we had profiled using 
oligonucleotide microarrays. Tumor tissues had been collected from 326 patients with 
invasive adenocarcinoma who underwent initial surgery at the Institut Paoli-
Calmettes (Marseilles, France) between 1987 and 2007. Each patient gave written 
informed consent and the study was approved by our institutional review board. 
Samples were macrodissected and frozen in liquid nitrogen within 30 min of removal. 
All specimens contained >60% of tumor cells (as assessed before RNA extraction 
using frozen sections adjacent to the profiled samples). After surgery, patients were 
treated using a multimodal approach according to standard guidelines. DNA and 
RNA were extracted from frozen samples by using guanidium isothiocynanate and 
cesium chloride gradient as described previously [10]. RNA integrity was controlled 
on Agilent Bioanalyzer (Agilent Technologies). We had also profiled 11 normal breast 
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(NB) tissue samples pooled in 4 RNA samples. Expression profiles had been 
established for these 326 cancers and 4 NB pools with Affymetrix U133 Plus 2.0 
human oligonucleotide microarrays as previously described [11]. Scanning was done 
with Affymetrix GeneArray scanner and quantification with Affymetrix GeneChip 
Operating Software. Data were analyzed by the Robust Multichip Average method 
[12] in R using Bioconductor and associated packages. PARP1 expression was 
measured by analyzing the sole probe set present on our Affymetrix microarrays, ID 
208644_at. Before analysis, gene expression levels for each tumor sample were 
centered by the average expression levels of the four NB samples. All data were then 
log2 transformed for display and analysis. 
To examine the correlation between PARP1 mRNA expression and histo-
clinical features of tumors in a large series of samples, we analyzed 12 publicly 
available datasets collected from the National Center for Biotechnology Information 
(NCBI)/ Genbank GEO database (series entry GSE2034, GSE2990, GSE4922, 
GSE1456, GSE7390, GSE2741, GSE1992, GSE2740, GSE2607, GSE6130, 
GSE3165, GSE6128, GSE10886) or at the following web addresses 
http://bioinformatics.mdanderson.org/pubdata.html;http://microarray-
pubs.stanford.edu/wound_NKI/ ; http://www.rii.com/publications/2002/vantveer.html. 
To be comparable across datasets and to exclude bias from population 
heterogeneity, PARP1 expression levels were standardized within datasets using the 
luminal A population as reference. Combined with our IPC series, this resulted in a 
total of 2,485 invasive breast cancers with PARP1 expression and histo-clinical data 
available for meta-analysis (Table 1). 
The molecular subtypes related to the Stanford intrinsic breast cancer 
classification were determined using Single Sample Predictor (SSP) classifier based 
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on a list of 306 intrinsic genes [13]. Briefly, after having identified the genes common 
between the intrinsic gene set and each expression dataset, we then used Distance 
Weighted Discrimination (DWD) [14] to normalize each dataset in order to be 
comparable to the 315 samples of the Hu‟s combined test sample set. Next, we 
defined the expression centroid of each subtype for the common probe sets in this 
combined test sample set [13]. Finally, we measured the correlation of each sample 
with each centroid. The sample was attributed the subtype corresponding to the most 
correlated centroid.  
 
Array-comparative genomic hybridization data of breast cancer 
Our analysis included data of genomic imbalances of 260 out of the 326 breast 
tumors. Data had been generated by array-comparative genomic hybridization 
(aCGH) using 244K CGH Microarrays (Hu-244A, Agilent Technologies) following a 
described protocol [10]. A pool of 13 normal male DNA had been used as reference. 
Scanning was done with Agilent Autofocus Dynamic Scanner (G2565BA, Agilent 
Technologies). Data analysis was done as described [10]. Extraction of data (log2 
ratio) was done from CGH Analytics, whereas normalized and filtered log2 ratio was 
obtained from „„Feature Extraction‟‟ software (Agilent Technologies). The PARP1 
locus at 1q41 was analyzed and copy number changes were characterized as 
reported previously [10]. Eight probes matched the PARP1 gene on our Agilent 
chips. A tumor was considered as harboring a gain for PARP1 if at least 5 (out of 8) 
consecutive probes displayed a log2 ratio tumor/normal >|0.5|.  
 
Statistical analyses 
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Study is retrospective and multicentric based on a large public data set. 
Comparisons of mean PARP1 expression level according to classical histo-clinical 
factors were done using Student t-test (2 variables) or one-way analysis of variance 
(ANOVA; more than 2 variables). Metastasis-free survival (MFS) was calculated from 
the date of diagnosis until date of distant relapse and follow-up was measured from 
the date of diagnosis to the date of last news for patients without relapse. Overall 
survival (OS) was calculated from the date of diagnosis until date of death and follow-
up was measured from the date of diagnosis to the date of last news for patients 
without death. Survival curves were generated using Kaplan-Meier method and 
compared with the log-rank test. Univariate and multivariate analyses were done 
using Cox regression analysis. Variables tested in univariate analysis included 
patients‟age at time of diagnosis (≤50 years vs >50), pathological axillary lymph node 
status (pN: negative vs positive), pathological tumor size (pT: pT1 vs pT2-4), 
pathological grade (I vs 2-3), immunohistochemical (IHC) estrogen receptor (ER), 
progesterone receptor (PR), and ERBB2 status (negative vs positive), and PARP1 
mRNA expression (continuous value). Variables with a p-value <0.10 in univariate 
analysis were tested in multivariate analysis. All statistical tests were two sided at the 
5% level of significance. Statistical analysis was done using the survival package 
(version 2.30) in the R software (version 2.4.1; http://www.cran.r-project.org/). We 
followed the reporting recommendations for tumour marker prognostic studies 
(REMARK) [15].  
 
 
Results  
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PARP1 mRNA expression and DNA copy number: IPC series 
We analyzed expression data generated using Affymetrix microarrays from 
330 samples including 326 pre-treatment primary breast cancers and 4 NB samples 
collected at our institution. First, we observed that PARP1 mRNA expression was 
highly heterogeneous, with expression level varying across a large dynamic range 
and encompassing almost four base 2 logs. To address the impact of potential intra-
tumor heterogeneity in this pattern, we took advantage of recently published 
microarray data generated from a series of 18 breast cancer samples [16]. In this 
study, gene expression profiles obtained from 2 to 3 biopsy replicates of the same 
tumor sample were available for comparison; we observed an intra-patient PARP1 
mRNA expression variance significantly lower than inter-patient variance (p=9.19E-
29, ANOVA), suggesting that intra-tumor heterogeneity has a minor influence on the 
heterogeneous expression of PARP1 we have observed.  
Whole-genome hierarchical clustering showed that PARP1 was located within 
a proliferation gene cluster, including for example MKI67 and PCNA, along with other 
genes involved in DNA damage repair such as RAD51 and ERCC4. Of note, PARP1 
expression did not correlate with BRCA1 and BRCA2 expression (data not shown). 
Compared to NB, PARP1 was overexpressed (≥2-fold increase) in 58% of 
cancer samples (Figure 1a). Array-comparative genomic hybridization (aCGH) data, 
simultaneously available for 260 of the 326 samples, allowed us to analyze the 
PARP1 locus at 1q41. Amplification of the 1q41-q44 region is a frequent genetic 
alteration in breast cancer [17-19]. A significant genomic gain (log2 ratio>|0.5|) or 
amplification (log2 ratio>|1|) was observed in 91 out of 260 (35%) samples (the mean 
percent of probes displaying this copy number alteration was 99.2% [95CI, 97.8 – 
100] within the 91 altered tumors). Moreover, a significant association between 
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PARP1 mRNA expression and gene copies was observed: the mean expression 
level of PARP1 mRNA was more than twice higher in tumors with PARP1 gain or 
amplification compared with tumors displaying a normal gene copy number (p<1.E-8, 
t-test; Figure 1b). However, gain/amplification was not the sole mechanism of 
overexpression, which was also found in tumors without any gene copy number gain. 
 
PARP1 mRNA expression and histo-clinical correlations: meta-analysis 
Meta-analysis examined correlations between PARP1 mRNA expression and 
histo-clinical features of tumors in a dataset of 2,485 invasive breast cancer samples, 
including our series and 12 public microarray datasets. As shown in Table 2, PARP1 
expression was significantly (t-test) associated with immunohistochemical (IHC) 
negativity for estrogen receptor (ER), progesterone receptor (PR) and ERBB2, with 
high grade, histological type (being the highest in medullary cancers and the lowest 
in lobular tumors), high pathological tumor size, with a trend for axillary lymph node 
involvement (p=0.067), but not with age. For 430 cases with available IHC 
information, PARP1 expression was higher in TN samples (negative for ER, PR and 
ERBB2), compared to ERBB2+ (positive for ERBB2, whatever the ER and PR status) 
and ERBB2-/HR+ (positive for ER and/or PR, negative for ERBB2) samples (p=0.05, 
one-way ANOVA, data not shown).  
We looked for PARP1 expression in the transcriptional molecular subtypes 
defined by the intrinsic gene set [13]. PARP1 was overexpressed in basal samples 
compared to other subtypes (Figure 2). Interestingly, PARP1 expression was much 
more tightly associated with the basal subtype than with the TN subgroup. Indeed, 
among the 430 above-described cases with available IHC classification, the 
correlation of PARP1 mRNA with the molecular subtypes (basal, ERBB2, and others) 
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was high (p=4.6E-6, one-way ANOVA) and greatly superior to that observed with the 
IHC classification (data not shown). Examining the sole IPC dataset (where 
simultaneous mRNA and genomic data were available), it was possible to address 
within each molecular subtype the above-described association between PARP1 
expression and gene copy gain. The association was significant (t-test) in basal 
(p=5.06E-4), ERBB2 (p=7.2E-3) and luminal B (p=6.28E-3) samples, but not in 
luminal A and normal samples. PARP1 was overexpressed in 84, 100 and 79% of 
PARP1-amplified/gained basal, ERBB2 and luminal B samples, respectively, versus 
61 and 50% of luminal A and normal samples, respectively.  
Finally, we examined the prognostic impact of PARP1 expression, along with 
other known clinical or pathological factors. We first examined MFS. In this series, 
follow-up was available for 1,637 patients: 494 women developed metastatic relapse 
with a median time to relapse of 32 months, and 1,143 remained relapse-free with a 
median follow-up of 96 months. In univariate analysis, PARP1 expression (together 
with pN, pT, grade, and ER, PR, and ERBB2 IHC status) was associated with a 
worse MFS (HR=1.12 [1.04-1.22]; p=0.004; Figure 3a). However, this was not 
maintained in multivariate analysis (data not shown). Since potential prognostic 
factors for MFS may interact with and thus be confounded by systemic adjuvant 
therapies, we re-analyzed data according to the treatment received, adjuvant 
chemotherapy and/or hormonal therapy, no patient being exposed to adjuvant 
trastuzumab. There were 261 patients who had not received any adjuvant systemic 
therapy (subgroup CT0HT0). Among them, 91 developed metastatic relapse with a 
median time to relapse of 27 months, and 170 remained relapse-free with a median 
follow-up of 99 months. There were 602 patients who had not received any adjuvant 
chemotherapy, with or without hormonal therapy (subgroup CT0HT+/-), including 210 
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who experienced metastatic relapse with a median time of 28 months, and 392 who 
did not relapse with a median follow-up of 100 months. As shown in Table 3 and 
Figure 3a, PARP1 mRNA expression was associated with a worse MFS in univariate 
analysis in both subgroups (HR=1.25 [1.04-1.51], p=0.017 in subgroup CT0HT0, and 
HR=1.12 [0.994-1.27], p=0.063 in subgroup CT0HT+/-). In both subgroups, PARP1 
expression remained an independent prognostic factor for MFS in multivariate 
analysis (HR=1.24 [1-1.53], p=0.054 in subgroup CT0HT0, and HR=1.24 [1.02-1.51], 
p=0.035 in CT0HT+/-. By contrast, in 334 patients identified as having received 
adjuvant chemotherapy (103 with metastatic relapse with a median time to relapse of 
27 months, and 231 without any metastatic relapse with a median follow-up of 71 
months), no correlation existed between PARP1 expression and MFS (HR=1.03 
[0.87-1.22], p=0.72; Figure 3a). 
Regarding OS, follow-up was available for 1,115 patients: 285 women died 
with a median time of 49 months and 830 were alive with a median follow-up of 100 
months. In univariate analysis, PARP1 expression was associated with a worse OS 
(HR=1.16 [1.04-1.29]; p=0.006; Figure 3b). However, this was not maintained in 
multivariate analysis (data not shown). In the CT0HT0 subgroup (163 patients with 
available follow-up), 43 patients died with a median time of 46 months and 120 were 
alive with a median follow-up of 108 months. In the CT0HT+/- subgroup, 213 patients 
had follow-up data available, including 53 who died with a median time of 47 months 
and 160 alive with a median follow-up of 101 months. In the CT1 subgroup (326 
patients with available follow-up), 93 patients died with a median time to death of 41 
months and 233 were alive with a median follow-up of 74 months. No significant 
association was found between PARP1 expression and OS in any subgroup 
(HR=1.23 [0.93-1.62], p=0.15 in CT0HT0; HR=1.18 [0.92-1.52], p=0.2 in CT0HT+/-; 
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HR=1.13 [0.94-1.36], p=0.18 in CT1), even though trends similar to MFS (lower 
survival in high PARP1-expressing tumors in untreated patients only) were observed 
(Figure 3b). 
 
 
Discussion 
 
To date PARP1 mRNA expression and DNA copy number alterations have not 
been described in breast cancer. In this large series, we show that PARP1 
expression is heterogeneous, with overexpression found in a significant number of 
breast cancers, in part due to genomic gain/amplification. This is particularly true in 
TN and even more in basal samples, and to a lesser degree in ERBB2+ and luminal 
samples. However, the role of such an overexpression in tumor initiation or 
progression, if any, remains to be elucidated. In addition, and for the first time to our 
knowledge, we have shown a significant and independent association between 
PARP1 expression and metastasis-free survival in breast cancer. Importantly, this 
association was restricted to patients not treated with any adjuvant chemotherapy. 
Exploiting DNA repair alterations using PARP inhibition [4, 5] was recently 
shown as a promising approach in BRCA-mutated or TN breast cancers, which are 
classically associated with the basal subtype [20]. Thus, in a phase I dose-escalation 
study, Fong and colleagues selected a population enriched in BRCA-associated 
cancers [4]. In the overall population, there was no objective response. In the group 
of 19 patients with a documented BRCA mutation, including breast, ovarian, and 
prostate malignancies, there was a 47% response rate and a 63% clinical benefit 
rate. In TN breast cancer, a randomized phase II study compared addition of a 
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PARP1 inhibitor, BSI-201, to chemotherapy with gemcitabine and carboplatin versus 
chemotherapy alone [5]. Preliminary data demonstrated that the addition of BSI-201 
was associated with highly significant improvements in response (from 16% to 48%), 
in progression-free survival (median from 3.3 to 6.9 months), as well as overall 
survival. A randomized phase III study is currently underway to confirm these results 
with gemcitabine, carboplatin, and BSI-201. Moreover, cisplatin-based neoadjuvant 
treatment [21] provided dramatic pathological response rate (nearly 75%) in a small-
sized population of tumors occurring in BRCA-mutated patients. In addition, cisplatin 
as single-agent induced a promising response rate of 22% in TN breast cancer, 
which was correlated with low BRCA expression [22]. These convergent clinical data 
suggest that tumors with deficient DNA-repair phenotypes, thought to be enriched in 
BRCA–mutated and TN subtypes, could be very sensitive to PARP inhibitors and 
DNA-damaging agents, alone or in combination. However, reliable and robust 
biomarkers that allow the accurate identification of alterations in functional DNA 
repair pathways (the so-called “BRCAness” phenotype, with the highest probability to 
benefit from these therapies) are still lacking. It still remains to be demonstrated 
whether the major increase in PARP1 expression observed in our study in some 
breast cancers might be such a marker. Speculatively, it could reflect a regulatory 
response to genetic instability, aiming to compensate for an abnormal rate of DNA 
damages, explaining why this event is more pregnant in the most instable subtypes, 
such as TN and basal. In this regard, our observation that the prognostic value of  
PARP1 expression was lost in patients receiving adjuvant chemotherapy could 
suggest that overexpression of PARP1 may be associated with tumor sensitivity to 
cytotoxic treatment, essentially cyclophosphamide and/or anthracycline-based in our 
retrospective series. Such an hypothesis is consistent with the recently reported 
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positive correlation between PARP1 protein expression and response to neoadjuvant 
chemotherapy [23, 24]. In this study, 646 breast cancer samples from the GeparTrio 
neoadjuvant phase III trial were centrally stained by IHC for PARP protein. Similarly 
to what we observed at the mRNA level, PARP protein was found in all molecular 
subtypes, more frequently in ERBB2-positive and TN tumors, and correlated with 
most known prognostic factors, including poor differentiation, non-lobular histological 
type and negative hormonal receptivity. Notably, PARP expression independently 
predicted for the pathological complete response (pCR) to neoadjuvant taxane-
anthracycline-based chemotherapy: patients with high expression showed a pCR rate 
of 25.7% compared to 18.8% and 6.1% in patients with medium or low expression 
(p<0.001). Interestingly, it is worth emphasizing that the deficient DNA-repair 
phenotype may be observed beyond these subtypes. For example, recent data have 
suggested that PTEN deficiency may associate with reduction in RAD51 expression 
and perturbation of homologous recombination in BRCA-intact human cancer cells, 
leading to high sensitivity to PARP inhibition [25]. Moreover, a similar deficiency in 
DSBs repair may be functionally induced in various non-genetic conditions, including 
hypoxia or even PARP inhibition itself, both setting being associated with a 
repression in BRCA1 and RAD51 transcription and therefore an increased efficiency 
of anti-PARP treatment [26]. Altogether, these data support the hypothesis that 
PARP inhibition may have broader applications in breast cancer treatment than 
anticipated based on initial preclinical and clinical results. 
In conclusion, we report the first large-scale integrated analysis of PARP1 
expression and genomic status in breast cancer. Whether PARP1 overexpression 
may identify breast cancers with higher probability of response to PARP inhibitors or 
DNA-damaging agents needs to be determined. But, if this hypothesis were 
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confirmed, our data should not only strengthen the interest for these compounds in 
basal breast cancers, but also suggest promising applications in a larger fraction of 
patients, beyond the basal subtype.  
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Table 1: Histo-clinical characteristics of the 2,485 breast cancer patients. 
Variables and categories N (%) 
Sex  
            Female 2485 (100%) 
Age (years)  
 ≤50 897 (51%) 
 >50 856 (49%) 
Histological type  
 DUC 495 (79%) 
 LOB 35 (6%) 
 MIX 30 (5%) 
 MED 24 (4%) 
 TUB 6 (1%) 
 MUC 5 (1%) 
 Other 32 (5%) 
Pathological axillary lymph node invasion 
(pN) 
 
 No 1280 (66%) 
 Yes 671 (34%) 
Pathological tumour size (pT)  
 pT1 753 (40%) 
 pT2 877 (47%) 
 pT3 169 (9%) 
 pT4 65 (3%) 
Grade  
 1 337 (16%) 
 2 820 (39%) 
 3 932 (45%) 
ER (IHC)  
 Negative 653 (32%) 
 Positive 1362 (68%) 
PR (IHC)  
 Negative 306 (42%) 
 Positive 418 (58%) 
ERBB2 (IHC)  
 Negative 334 (78%) 
 Positive 96 (22%) 
Adjuvant chemotherapy  
 No 625 (57%) 
 Yes 480 (43%) 
Chemotherapy regimen  
CMF 10 (2%) 
AC 195 (40%) 
AC-T 165 (34%) 
Unknown 110 (24%) 
Adjuvant hormonal therapy  
 No 815 (76%) 
 Yes 254 (24%) 
Follow-up (months)  
 Median 96 
Metastatic relapse  
 No 1143 (70%) 
 Yes 494 (30%) 
 21 
DUC = ductal; LOB = lobular; MED = medullary; MIX = mixed;  
MUC = mucinous; TUB = tubular; CMF= cyclophosphamide, 
methotrexate, 5 Fluorouracile regimen; AC = anthracycline, 
cyclophosphamide regimen; AC-T= anthracycline, cyclophosphamide, 
taxane regimen. 
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Table 2: PARP1 mRNA expression according to histo-clinical features in 2,485 
breast cancer samples. 
 
Variables and categories 
(N) 
Mean PARP1 mRNA 
expression (log2) 
p-value 
Age (years) 
< 50 (897) 
> 50 (856) 
Histological type 
DUC (495) 
LOB (35) 
MED (24) 
MIX (30) 
MUC (5) 
TUB (6) 
Other (32) 
Pathological axillary lymph node invasion 
(pN) 
no (1280) 
yes (671) 
Pathological tumour size (pT) 
pT1 (753) 
pT2 (877 
pT3 (169) 
pT4 (65) 
Grade 
1 ( 337) 
2 ( 820) 
3 (932) 
ER (IHC) 
positive (653 
negative (1362) 
PR (IHC) 
positive (306) 
negative (418) 
 
ERBB2 (IHC) 
positive (96) 
negative (334) 
 
1.08 
1.12 
 
1.15 
0.85 
2.61 
0.77 
0.96 
0.95 
1.37 
 
1.08 
1.18 
 
 
0.98 
1.16 
1.30 
1.29 
 
0.67 
0.96 
1.32 
 
1.02 
1.28 
 
1.04 
1.24 
 
 
0.96 
1.21 
0.44 
 
 
4.49E-9 
 
 
 
 
 
 
 
0.067 
 
 
 
0.0007 
 
 
 
 
4.64E-20 
 
 
 
7.27E-6 
 
 
0.018 
 
 
 
0.05 
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Table 3: Univariate and multivariate analyses in MFS in patients untreated with 
systemic adjuvant chemotherapy 
 
A/ Subgroup CT0HT0 
 Univariate  Multivariate 
Variables N HR [CI95%] 
p-
value 
 N HR [CI95%] 
p-
value 
Age >50 261 0.81 [0.49-1.31] 0.38     
ER (IHC) pos 259 0.58 [0.38-0.89] 0,012  133 0.69 [0.4-1.19] 0,18 
PR (IHC) pos 38 0.77 [0.21-2.87] 0,695     
ERBB2 (IHC) pos 34 NA NA     
pN pos 134 2.88 [1.66-5] 0,0001  133 2.12 [1.22-3.7] 0,0078 
pT T2-4 260 2.07 [1.37-3.13] 0,0005  133 1.83 [1.07-3.12] 0,027 
Grade 2-3 259 4.15 [2.01-8.59] 0,0001  133 2.22 [0.76-6.46] 0,14 
mRNA PARP1 261 1.25 [1.04-1.51] 0,017  133 1.24 [1-1.53] 0,054 
        
B/ Subgroup CT0HT+/- 
 Univariate  Multivariate 
Variables N HR [CI95%] 
p-
value 
 N HR [CI95%] 
p-
value 
Age >50 316 0.76 [0.50-1.17] 0.21     
ER (IHC) pos 600 0.72 [0.54-0.97] 0,029  166 0.6 [0.36-0.98] 0,042 
PR (IHC) pos 73 0.85 [0.3-2.47] 0,772     
ERBB2 (IHC) pos 65 0.00 [0.00-Inf] 1     
pN pos 456 2.5 [1.66-3.78] 
1,35E-
05 
 166 2.34 [1.42-3.84] 0,0008 
pT T2-4 314 2.18 [1.47-3.24] 0,0001  166 1.59 [0.98-2.58] 0,059 
Grade 2-3 312 4.24 [2.14-8.4] 
3,54E-
05 
 166 1.99 [0.83-4.76] 0,12 
mRNA PARP1 602 1.12 [0.99-1.27] 0,063  166 1.24 [1.02-1.51] 0,035 
 
NA, not applicable (no ERBB2-positive patient) 
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Legends of Figures 
 
Figure 1: mRNA expression of PARP1 in breast cancer.  
a/ PARP1 expression across 326 breast cancer (BC) samples profiled using 
Affymetrix U133 Plus 2.0 human oligonucleotide microarrays. Expression levels in 
tumors are reported as a box plot relatively to expression in normal breast (NB, 
horizontal solid line). Median and ranges are indicated. Overexpression in tumors 
was defined as a ratio of expression tumor/NB ≥2 (horizontal dashed line).  
b/ Expression across 260 BC samples profiled also by aCGH using 244K CGH 
microarrays (Hu-244A, Agilent Technologies). Box plots of PARP1 expression in BC 
are shown according to PARP1 genomic status, with (left) and without (right) gain 
defined as a DNA copy number ratio tumor/NB ≥2 (horizontal dashed line). 
Differences in PARP1 expression levels between both groups were tested for 
significance using Student t-test. For each box plot, median and ranges are 
indicated. 
 
Figure 2: mRNA expression of PARP1 according to breast cancer molecular 
subtypes.  
PARP1 expression across 2,485 breast cancer (BC) samples with publicly available 
data was examined according to molecular subtypes as defined in [13]. Box plots of 
PARP1 expression in BC are shown according to basal, ERBB2, luminal A and B, 
and normal-like subtypes. Differences in PARP1 expression levels between the 
subtypes were tested for significance using one-way ANOVA. For each box plot, 
median and ranges are indicated.  
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Figure 3: Metastasis-free and overall survivals according to PARP1 mRNA 
expression. 
a/ Kaplan-Meier MFS curves in patients with high (ratio of expression tumor/NB ≥2) 
and low (ratio of expression tumor/NB <2) expression of PARP1 mRNA: all patients 
(left), untreated patients (CT0HT0, middle), and patients treated with adjuvant 
chemotherapy (CT1, right).   
b/ Kaplan-Meier OS curves (the legend is similar to a/). 
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